Detailed Information on Publication Record
2017
Betablokátory v registru chronického srdečního selhání FAR NHL
LÁBR, Karel, Jindřich ŠPINAR, Jiří PAŘENICA, Lenka ŠPINAROVÁ, F. MÁLEK et. al.Basic information
Original name
Betablokátory v registru chronického srdečního selhání FAR NHL
Name in Czech
Betablokátory v registru chronického srdečního selhání FAR NHL
Name (in English)
Beta-blockers in chronic heart failure as recorded in the FAR NHL registr
Authors
LÁBR, Karel (203 Czech Republic, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution), F. MÁLEK (203 Czech Republic), Monika ŠPINAROVÁ (203 Czech Republic, belonging to the institution), Ondřej LUDKA (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution) and Růžena LÁBROVÁ (203 Czech Republic, guarantor, belonging to the institution)
Edition
Kardiologická revue - Interní medicína, Praha, Ambit Media, 2017, 1212-4540
Other information
Language
Czech
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14110/17:00098136
Organization unit
Faculty of Medicine
Keywords (in Czech)
betablokátory; srdeční selhání; NT-proBNP; krevní tlak; farmakoterapie; ejekční frakce levé komory; kreatininová clearance
Keywords in English
adrenergic beta-antagonists; heart failure; pro-brain natriuretic peptide; blood pressure
Tags
Tags
International impact, Reviewed
Změněno: 22/3/2018 15:39, Soňa Böhmová
V originále
Úvod: Betablokátory (BB) jsou lékem první volby společně s inhibitory angiotenzin konvertujícího enzymu (ACEI) nebo blokátorů receptorů pro angiotenzin II (ARB) u pacientů se srdečním selháním se sníženou ejekční frakcí levé komory (heart failure with reduced ejection fraction – HFrEF), snižují morbiditu i mortalitu. Metodika: Data byla sbírána v rámci registru FARmakologie a NeuroHumoráLní aktivace (FAR NHL). Zařazeni byli alespoň měsíc stabilní pacienti s chronickým srdečním selháním s ejekční frakcí levé komory (EF LK) < 50 %.
In English
Background: Beta-blockers (BB) and angiotensin-converting-enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) are part of the first-line treatment of heart failure with reduced ejection fraction (HFrEF), leading to decreased morbidity and mortality. Methods: The data were collected from the Pharmacology and l Neurohumoral Activation Registry (FAR NHL). Patients with left ventricle ejection fraction (LV EF) under 50% who were stable for at least one month were included. Results: A total of 1,100 patients were included, median age was 65 years, 80.8% were male. Of all patients, 20% received low dose (LD), 57% medium dose (MD) and 17% high dose (HD). Of these, 6.2% of patients were not treated with BBs at all. The higher the blood pressure (BP; LD 124/77; MD 129/80; HD 132/82 mm Hg, p < 0.001), LV EF (LD 29.5; MD 30.5; HD 32.0%; p = 0.003), creatinine clearance rate (CrCl; LD 78.7; MD 87.8; HD 91.1 ml/min; p = 0.001) or body weight (LD 83.2; MD 88.7; HD 93.5 kg; p < 0.001) was, the higher the dose of BB they received. The lower the NT-proBNP level was, the higher the dose of BB they received (LD 767; MD 456; HD 314 pg/ml; p < 0.001). There was no difference in prescription of BB depending on the presence of atrial fibrillation (AF). Patients with AF were more often treated with digoxin or a combination of digoxin and BB than patients without AF (p < 0.001). Summary: Nearly 94% of HFrEF patients received BB, but only 17% received the target dose of BB. Ninety-nine % of patients treated with BB received one of the drugs recommended by the ESC Guidelines. The more severe the illness was, as expressed by lower BP, CrCl, LV EF, body weight and higher NT-proBNP, the lower the dose of BB the patients received and tolerated.
Links
| MUNI/A/1270/2015, interní kód MU |
|